Perimenopause

See my Evidence Standards for how I grade the research below.

The Core Problem: Instability, Not a Simple Decline

Perimenopause is the transition a woman's body goes through as ovarian reserve declines, a process that can start becoming physiologically active around age 35 for many women, though the timing varies widely. It is not a steady drop in estrogen. Every ovary is born with a fixed, finite supply of follicles, and that supply declines continuously from birth. As it thins, the granulosa cells inside the remaining follicles produce less inhibin B, a hormone whose main job is to hold FSH in check at the pituitary. When inhibin B falls, that brake loosens, and FSH climbs, often years before a woman notices any change in her cycle.

Rising FSH does not simply produce a rising, steady level of estrogen. It overstimulates whatever follicles are left, and the ovarian response to that overstimulation is erratic: some cycles produce a surge of estradiol well above a woman's normal premenopausal baseline, and others produce very little. The net pattern across early and mid perimenopause is volatility, not a smooth downward slope. A true, sustained fall in estradiol is a late finding, typically only in the few years immediately before the final period.

Burger HG, Hale GE, Robertson DM, Dennerstein L. "A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project." Human Reproduction Update. 2007;13(6):559-565. Longitudinal data from this cohort confirmed that estradiol levels are often preserved or even elevated through most of the transition, with occasional values several times a premenopausal baseline, and only decline sharply in late perimenopause, driven by the fall in inhibin B and the resulting rise in FSH.

Longitudinal Cohort Endpoint: Estradiol/FSH/Inhibin B Trajectories Across the Transition

This is the physiological reason perimenopause can feel so unpredictable. A woman can have a week that feels like classic high estrogen (breast tenderness, bloating, heavier bleeding) followed by a week that feels like estrogen deficiency (hot flashes, night sweats, dryness), because both states are real and both are happening within the same transition, sometimes within the same month.

Losing Ovulation, Not Just Losing Eggs

The other half of the picture is progesterone, and it depends entirely on ovulation. Progesterone is only produced in meaningful amounts by the corpus luteum, the structure that forms after an egg is released. As perimenopause progresses, more cycles become anovulatory, meaning no egg is released at all, even though a cycle and some bleeding pattern may still occur. An anovulatory cycle makes no corpus luteum, which means no luteal-phase progesterone that month.

Because this happens gradually and unevenly, total progesterone exposure across a year starts declining well before periods become obviously irregular, often while estradiol is still fluctuating at or above baseline as described above. The combination of relatively unopposed estrogen and falling progesterone, sometimes called estrogen dominance, has real physiological effects independent of the absolute estradiol level: bloating, breast tenderness, breakthrough or heavier bleeding, and skin breakouts. Progesterone itself has a calming, sedating effect on the brain through its metabolite allopregnanolone, which acts on GABA receptors, so losing it disproportionately shows up as insomnia, anxiety, and mood instability, sometimes before a woman notices any other sign that her cycles are changing.

Prior JC. "Progesterone for Symptomatic Perimenopause Treatment - Progesterone Politics, Physiology and Potential for Perimenopause." Facts, Views & Vision in ObGyn. 2011;3(2):109-120. This review makes the case that ovulatory disturbances, not estrogen deficiency, are the primary driver of early perimenopausal symptoms. Progesterone's withdrawal, through loss of its calming neurosteroid effects, and the resulting relative estrogen excess account for much of the insomnia, anxiety, heavy bleeding, and breast tenderness reported in this phase.

Narrative Review Endpoint: Ovulatory Disturbance as Symptom Driver

Testosterone Is Also Declining, Just on a Different Timeline

Testosterone in women is produced by both the ovaries and the adrenal glands, and unlike estradiol and progesterone, it does not wait for perimenopause to start declining. Levels fall gradually and roughly linearly from a woman's twenties onward, at a pace on the order of one to two percent a year, with no sharp drop specifically tied to the menopausal transition itself. By the time a woman reaches her forties, that slow decline has often already added up to a meaningful reduction from her twenties baseline, and it continues on the same trajectory through perimenopause and beyond.

Davison SL, Bell R, Donath S, Montalto JG, Davis SR. "Androgen Levels in Adult Females: Changes with Age, Menopause, and Oophorectomy." Journal of Clinical Endocrinology & Metabolism. 2005;90(7):3847-3853. In a cross-sectional study of over 1,400 women aged 18 to 75, total and free testosterone declined steadily with age from the mid-reproductive years onward, with no discrete change in level at the time of natural menopause itself.

Cross-Sectional (n=1,423) Endpoint: Total and Free Testosterone by Age

Because it moves independently of the estradiol and progesterone volatility described above, testosterone's contribution to how a woman feels in her forties, low energy, reduced libido, harder-to-maintain muscle and worsening body composition despite consistent effort, tends to be a steadier background problem rather than one that swings week to week.

How This Gets Staged Clinically

The framework most reproductive endocrinologists use to stage this transition is called STRAW+10. The early menopausal transition is marked by persistent variability in cycle length of seven days or more from one cycle to the next, along with an FSH that is elevated but still inconsistent from month to month. The late menopausal transition is marked by stretches of 60 days or more without a period, an FSH consistently above 25 IU/L on a random draw, and more pronounced hormonal swings; this stage typically lasts one to three years. Menopause itself is defined only in retrospect, as 12 consecutive months without a period.

Harlow SD, Gass M, Hall JE, et al. "Executive Summary of the Stages of Reproductive Aging Workshop + 10 (STRAW+10)." Fertility and Sterility. 2012;97(4):843-851. This consensus framework defines the early transition by persistent cycle-length variability of 7 or more days, and the late transition by 60 or more days of amenorrhea with FSH above 25 IU/L, concluding with 12 months of amenorrhea marking menopause.

Consensus Staging Framework Endpoint: Cycle-Length and FSH Criteria by Stage

Two things are worth noting about that framework. First, it is a staging system built for research, not a checklist I run through at a visit, because the hormone criteria within it are exactly as volatile as everything described above. Second, the staging criteria only describe changes in bleeding pattern and FSH. They say nothing about symptoms, which is exactly why the symptom pattern below can, and often does, start well before a woman's cycle looks different enough to meet either stage's definition.

Why Hot Flashes Happen: The Brain, Not Just the Ovaries

Hot flashes are not simply a local response to low estrogen. Estrogen normally restrains a group of neurons in the hypothalamus called KNDy neurons (named for the three signals they produce: kisspeptin, neurokinin B, and dynorphin), which also happen to sit next to the brain's core temperature control center. When estrogen's restraint on those neurons is lost, whether from a sustained drop or the erratic swings of perimenopause, KNDy neuron activity increases and effectively resets the brain's thermostat, triggering the sudden vasodilation and sweating of a hot flash even though nothing in the room has changed.

Mittelman-Smith MA, Williams H, Krajewski-Hall SJ, McMullen NT, Rance NE. "Role for Kisspeptin/Neurokinin B/Dynorphin (KNDy) Neurons in Cutaneous Vasodilatation and the Estrogen Modulation of Body Temperature." Proceedings of the National Academy of Sciences. 2012;109(48):19846-19851. KNDy neurons in the hypothalamus mediate the estrogen-dependent modulation of core body temperature, and loss of estrogen's restraint on these neurons drives the vasodilation responsible for hot flashes.

Animal Model, Mechanistic Endpoint: KNDy Neuron Activity and Thermoregulation

The Symptom Pattern, and Why No Two Women Get the Same List

No one gets every symptom on this list, and it isn't a checklist that has to be fully checked off before perimenopause is worth considering. Any one of these, on its own, especially in a woman in her mid-thirties to late forties, can be an early sign, not just the hot flashes most people associate with the word:

Cycle changes: shorter or longer cycles, heavier or lighter bleeding, or skipped periods
Hot flashes or night sweats
Insomnia or fragmented sleep, independent of hot flashes
New or worsening anxiety, irritability, or mood instability
Breast tenderness, bloating, or skin breakouts
Low libido
Low energy or fatigue that doesn't track with sleep or effort
Brain fog or difficulty concentrating
Changes in body composition or difficulty maintaining muscle despite consistent training
Joint aches
Vaginal dryness, more often a later finding as estradiol's decline becomes sustained

Because estradiol, progesterone, and testosterone are moving on three different timelines for three different reasons, as described above, the mix and severity of these symptoms varies enormously from one woman to the next, and even from one month to the next in the same woman.

Why a Single Lab Draw Often Comes Back Normal

If estradiol and FSH can each swing widely within the same month, a single blood draw is a snapshot of a system in motion, not a stable measurement. A level drawn on a high-estradiol day can look entirely unremarkable even in a woman with significant symptoms, and a level drawn on a low day can look like early menopause in a woman who is only a few years into the transition. This is why perimenopause is, and should be, a clinical diagnosis built from age, symptom pattern, and cycle history, not a single number on a lab report.

What This Doesn't Mean

Not everything that shows up in a woman's late thirties or forties is perimenopause. Thyroid dysfunction, anemia, depression, and sleep apnea all overlap heavily with this symptom list and deserve their own evaluation rather than being assumed away. Perimenopause and any of those conditions can also coexist, and treating one doesn't rule out the other. The point of understanding this physiology isn't to self-diagnose from a symptom list. It's to recognize that a real, measurable process is underway even when a lab result looks unremarkable, and that it's a conversation worth having rather than waiting for it to become undeniable.

Perimenopause is a clinical diagnosis based on age, symptom pattern, and menstrual history. A single hormone level cannot reliably confirm or rule it out given the physiological volatility described above.

Next Step

This page covers the physiology of how and why perimenopause produces the symptoms it does. Whether hormone testing, timing, or treatment makes sense for you is an individual clinical decision made with your provider.

Already a patient? Bring this up at your next 4Ever Young visit. Have a question first?

Linktree DM on Instagram Email Dr. Wilcox